FDA Approves CELLCEPT — Genentech, Inc.

Following the expiration of key patents covering Mycophenolate Mofetil, market leaders such as Genentech, Inc. and its partner Roche will face increasing revenue pressure and heightened competition from a wave of new generic entries. This loss of exclusivity is expected to reshape the immunosuppressive landscape as interchangeable generics rapidly secure market share away from the brand name product (CELLCEPT).